Paradigm Biocapital Advisors LP
- SEC CIK
- 0001855655
- Latest filing
- Aug 14, 2026
TARS holding history
Tarsus Pharmaceuticals, Inc. in every 13F filed by Paradigm Biocapital Advisors LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
TARS overviewAll 13F holders of TARSFull Q2 2026 holdings
- Shares (Q2 2026)
- 2,775,649
- Value
- $174.7M
- % of portfolio
- 3.3%
- Quarters held
- 11
- Since Q4 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 2,775,649 | $174.7M | 3.3% | +213,495+8.3% | Added | Holders |
| Q1 2026 | 2,562,154 | $179.7M | 3.7% | 00.0% | Unchanged | Holders |
| Q4 2025 | 2,562,154 | $209.8M | 5.6% | −103,544−3.9% | Reduced | Holders |
| Q3 2025 | 2,665,698 | $158.4M | 4.7% | −310,401−10.4% | Reduced | Holders |
| Q2 2025 | 2,976,099 | $120.6M | 5.1% | +365,902+14.0% | Added | Holders |
| Q1 2025 | 2,610,197 | $134.1M | 6.2% | +78,301+3.1% | Added | Holders |
| Q4 2024 | 2,531,896 | $140.2M | 4.9% | +91,451+3.7% | Added | Holders |
| Q3 2024 | 2,440,445 | $80.3M | 2.8% | +5,029+0.2% | Added | Holders |
| Q2 2024 | 2,435,416 | $66.2M | 2.5% | −427,990−14.9% | Reduced | Holders |
| Q1 2024 | 2,863,406 | $104.1M | 3.7% | +1,838,406+179.4% | Added | Holders |
| Q4 2023 | 1,025,000 | $20.8M | 1.0% | +1,025,000 | New | Holders |